DelveInsight’s “Multiple System Atrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Multiple System Atrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Multiple System Atrophy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Multiple System Atrophy: An Overview
Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by symptoms that affect the autonomic nervous system (the part of the nervous system that controls involuntary action such as blood pressure or digestion) and movement. The symptoms reflect the progressive loss of function and death of different types of nerve cells in the brain and spinal cord.
According to Multiple System Atrophy Coalition (2021), MSA is broken down into two main subtypes based on the predominant symptom: MSA-predominant Parkinsonism (MSA-P) and MSA-predominant cerebellar ataxia (MSA-C). Over time, a patient diagnosed with MSA-P may appear to have MSA-C and vice versa, so these categorizations are not always set in stone.
Multiple System Atrophy Market Key Facts
-
The therapeutic market size of Multiple System Atrophy (MSA) in the 7MM was USD 125 million in 2021.
-
The United States accounts for the highest market size of Multiple System Atrophy (MSA), approximately 68% of the total market size in 7MM in 2021, in comparison to the other major markets, i.e., the EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
-
Among the EU5 countries, Germany had the highest market size, with USD 5 million in 2021, while Spain had the lowest multiple System Atrophy market size, with USD 3 million in 2021.
-
The market size for Multiple System Atrophy in Japan was estimated to be USD 21 Million in 2021, which accounts for 17% of the total 7MM market.
-
With the expected launch of the upcoming therapy TD-9855, the total market size of Multiple System Atrophy (MSA) is expected to show a change in the upcoming years.
-
The total diagnosed prevalent cases of Multiple System Atrophy in the 7MM were 36,000+ in 2021.
-
The highest prevalent diagnosed cases of Multiple System Atrophy were found in the US in 2021 (15,000+ cases), which are expected to show a rise in the future.
-
Among the major European countries, Germany had the highest total diagnosed prevalent cases of Multiple System Atrophy with 2,600+ cases, followed by Italy, which had 2,000 diagnosedprevalent cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent cases (1,500+ cases).
-
Japan had 10,900+ diagnosed prevalent cases of Multiple System Atrophy in 2021, accounting for approximately 30% of the 7MM.
-
Some of the leading companies in the Multiple System Atrophy therapeutics market include Ampreloxetine (TD-9855) (Theravance Biopharma), Safinamide(Zambon SpA), Lu AF82422 (Lundbeck A/S), BHV-3241 (Biohaven Pharmaceuticals), and Others.
Multiple System Atrophy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Multiple System Atrophy market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Multiple System Atrophy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Multiple System Atrophy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Multiple System Atrophy Epidemiology, Segmented by –
-
Total Diagnosed Prevalent Cases of Multiple System Atrophy (MSA)
-
Gender-specific Diagnosed Prevalent Cases of Multiple System Atrophy (MSA)
-
Age-specific Diagnosed Prevalent Cases of Multiple System Atrophy (MSA)
-
Type-specific Diagnosed Prevalent Cases of Multiple System Atrophy (MSA)
Multiple System Atrophy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple System Atrophy market or expected to be launched during the study period. The analysis covers the Multiple System Atrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Multiple System Atrophy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Multiple System Atrophy Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market
Multiple System Atrophy Therapeutics Analysis
There are approx. 20+ key companies developing therapies for Multiple System Atrophy. Currently, Biohaven Pharmaceuticals has its Multiple System Atrophy drug candidates in the most advanced stage of clinical development among all the key players.
The Leading Companies in the Multiple System Atrophy Therapeutics Market Include:
-
H Lundbeck A/S
-
Theravance Biopharma
-
Brain Neurotherapy Bio, Inc
-
Ionis Pharmaceuticals, Inc.
-
Alterity Therapeutics
-
Biohaven Pharmaceuticals
-
Alterity Therapeutics
-
Brain Neurotherapy Bio, Inc.
-
Biogen
-
Corestem, Inc.
-
Asklepios BioPharmaceutical
-
Inhibikase Therapeutics
-
RETROTOPE
-
Modag
-
AC Immune
-
Vaxxinity
-
Neuramedy
-
ProMIS Neurosciences
-
FAScinate Therapeutics
-
Wren Therapeutics
-
Blade Therapeutics
-
Stealth BioTherapeutics
And Many More
Multiple System Atrophy Drugs Covered in the Report Include:
-
Ampreloxetine (TD-9855): Theravance Biopharma
-
Lu AF82422: H Lundbeck A/S
-
Verdiperstat: Biohaven Pharmaceuticals
-
ATH434: Alterity Therapeutics
-
Safinamide: Zambon SpA
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Multiple System Atrophy Competitive Intelligence Analysis
4. Multiple System Atrophy Market Overview at a Glance
5. Multiple System Atrophy Disease Background and Overview
6. Multiple System Atrophy Patient Journey
7. Multiple System Atrophy Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Multiple System Atrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Multiple System Atrophy Unmet Needs
10. Key Endpoints of Multiple System Atrophy Treatment
11. Multiple System Atrophy Marketed Products
12. Multiple System Atrophy Emerging Drugs and Latest Therapeutic Advances
13. Multiple System Atrophy Seven Major Market Analysis
14. Attribute Analysis
15. Multiple System Atrophy Market Outlook (In US, EU5, and Japan)
16. Multiple System Atrophy Access and Reimbursement Overview
17. KOL Views on the Multiple System Atrophy Market
18. Multiple System Atrophy Market Drivers
19. Multiple System Atrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-market
Other Trending Healthcare Reports By DelveInsight
Multiple System Atrophy (MSA) Pipeline Insight
“Multiple System Atrophy – Pipeline Insight, 2023,” report provides comprehensive insights about 20+ companies and 20+ drugs in the Multiple System Atrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/